Maintenance lenalidomide for large-cell lymphoma: Who really benefits?

Thomas E. Witzig

doi:10.1200/JCO.2017.73.2578

Maintenance lenalidomide for large-cell lymphoma: Who really benefits?

Thomas E. Witzig

Hematology

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	2459-2460
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	35
Issue number	22
DOIs	https://doi.org/10.1200/JCO.2017.73.2578
State	Published - Aug 1 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2017.73.2578

Cite this

@article{938cf2a7305a48a2a646cdad3bf069f6,

title = "Maintenance lenalidomide for large-cell lymphoma: Who really benefits?",

author = "Witzig, {Thomas E.}",

year = "2017",

month = aug,

day = "1",

doi = "10.1200/JCO.2017.73.2578",

language = "English (US)",

volume = "35",

pages = "2459--2460",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "22",

}

TY - JOUR

T1 - Maintenance lenalidomide for large-cell lymphoma

T2 - Who really benefits?

AU - Witzig, Thomas E.

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85026736432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026736432&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.73.2578

DO - 10.1200/JCO.2017.73.2578

M3 - Editorial

C2 - 28514184

AN - SCOPUS:85026736432

SN - 0732-183X

VL - 35

SP - 2459

EP - 2460

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -

Maintenance lenalidomide for large-cell lymphoma: Who really benefits?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this